Complex treatment of ischemic heart disease (state after myocardial infarction, angina), heart rhythm disorders, intoxication with cardiac glycosides, treatment of cardiomyopathies of different Genesis , myocardiodystrophy (against the background of heavy physical exertion, infectious and endocrine Genesis), myocarditis; liver diseases (hepatitis, cirrhosis, fatty liver dystrophy); urocoproporphyria.
Release form, composition
The drug Riboxin is a solution for injection, which is produced in the form of a colorless transparent liquid.
The composition of 1 ml of the solution includes 20 g inosine as the main component, as well as additional substances: 1M sodium hydroxide solution, hexamethylenetetramine, water for injection.
10 ampoules in a carton pack, in one ampoule 5 ml of solution.
Riboxin belongs to the group of cardiological agents.
Due to its properties, the drug improves metabolic processes in the myocardium, increases the strength of heart contractions and the activity of a number of enzymes of the Krebs cycle, promotes more complete relaxation of the myocardium in diastole. Improves blood supply to tissues and coronary blood supply, activates tissue regeneration (in particular myocardium, intestinal mucosa and stomach).
Indications for use
Riboxin is used as part of complex treatment for:
- ischemic heart disease (heart rhythm disturbances, angina pectoris);
- glycosidic intoxication;
- cardiomyopathies of various origins;
- peptic ulcer of the stomach and duodenum;
- liver diseases (chronic and acute hepatitis, drug and alcoholic liver damage, liver cirrhosis and fatty liver disease);
- open-angle form of glaucoma.
The drug Riboxin is contraindicated for use in the presence of diseases such as gout, hyperuricemia. Also, the drug is not used by persons with increased susceptibility to the components of the drug and in childhood.
Pregnancy and breastfeeding period
The use of the drug Riboxin during pregnancy and lactation has not been studied.
Mode of application
Riboxin is intended for intravenous use.
At the beginning of treatment for adult patients, 10 ml of a 2% solution (200 mg) is administered once a day, if the drug is well tolerated, the dosage can be increased to 20 ml of a 2% solution (400 mg) 1-2 times a day. The solution is injected intravenously at a rate of 40-60 drops per minute or intravenously in a stream (slowly). With drip injection, Riboxin-Biopharma is diluted with 0.9% sodium chloride solution or 5% glucose solution (up to 250 ml).
The duration of therapy is 10-15 days.
An overdose of Riboxin is accompanied by the following symptoms: allergic reactions, exacerbation of gout, tachycardia, increased manifestations of adverse reactions. In case of drug intoxication, symptomatic treatment is used.
The use of the drug Riboxin very rarely causes side effects, but sometimes it is possible: itching, rash, skin flushing, an increase in the concentration of uric acid in the blood and tachycardia. With prolonged use or administration in high doses, exacerbation of gout may occur.
To store the drug, you should adhere to such simple conditions: the temperature is not more than + 25 ° C, in a dark place, and as far as possible from children.
The shelf life of the solution is 3 years from the date of production.